Welcome to USA CLINIX
Female sexual arousal disorder (or frigidity ) is the condition of decreased, insufficient, or absent lubrication in females during sexual activity, and sexual contact in females . Loss of interest in sex occurs most commonly in women as they age and approach menopause.
Although female sexual dysfunction (FSD) is currently a contested diagnostic, pharmaceutical companies are beginning to promote products to treat FSD, often involving low doses of testosterone.
Women's sexual health deserves equal attention
FSD covers at least four different conditions: problems with desire, arousal, achieving orgasm, and genital pain. The patch aims to increase libido in women. Doctors have used a range of other treatments for women, including various hormones, antidepressants, and male impotence drugs like Viagra , Levitra , Cialis and Icos . According to a P&G survey on female health 30 million women are naturally menopausal, 3 million are distressed by their lack of sexual desire, and 20% of 25 million women who are surgically menopausal are distressed.
Real Product!
Intrinsa Patches are approved for the treatment of Female Sexual Dysfunction and manufactured by company Proctor & Gamble. FSD refers to the deficiency or absence or sexual thoughts and desires in women, however it is not considered a disorder until it causes a patient considerable distress or relationship problems. Intrinsa is supplied in a patch form that contains the active substance testosterone, which is produced naturally in the ovaries in menopausal women.
How does Intrinsa work?
The level of testosterone in surgically post-menopausal women depletes rapidly, thereby affecting the sexual life of many women. Approximately one in five of these women could suffer from low sex drive as the removal of ovaries can cause women's testosterone levels to drop by as much as 50%. Decrease in testosterone level has been associated with low sexual desire, reduced sexual thoughts and sexual arousal. Intrinsa Patches works by supplying the sex hormone, testosterone, to such women and solving their sexual problems.
Testing and release to market:
- In P&G's studies over six months of surgically menopausal women, those who received a placebo said satisfying sexual activity increased by an average of 19%, vs. a 73% increase for Intrinsa patch users. In the placebo group, women had an average increase in satisfying sexual episodes of 0.5 per month, while those with patches had an average increase of 1.9 episodes per month.
- The patch was granted a license from the European Medicines Agency in July, and is available on Britain 's National Health Service from March 2007. It will initially only be available on prescription for post-menopausal women with diagnosed sexual problems.
|
